Skip to main
Telehealth Retatrutide

Tracking the triple-agonist evidence as it moves from Phase 2 toward the clinic.

The papers you can read

Where Are the Published Retatrutide Papers?

The numbered papers supply the findings; each link opens the study or review so you can read more.

Which paper supports the finding you are reading?

The number beside a finding names the corresponding paper in this list. You can open the link to read what researchers measured, which people took part and how their health changed.

  1. Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. ↗
  2. Rosenstock J, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial. Lancet. 2023;402(10401):529-544. ↗
  3. Li W, Zhou Q, Cong Z, Yuan Q, Li W, Zhao F, Xu HE, Zhao LH, Yang D, Wang MW. Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide. Cell Discovery. 2024;10:77. ↗
  4. Urva S, Coskun T, Loh MT, Du Y, Thomas MK, Gurbuz S, Haupt A, Benson CT, Hernandez-Illas M, D'Alessio DA, Milicevic Z. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Lancet. 2022;400:1869-1881. ↗
  5. Sanyal AJ, Kaplan LM, Frias JP, Brouwers B, Wu Q, Thomas MK, Harris C, Schloot NC, Du Y, Mather KJ, Haupt A, Hartman ML. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nature Medicine. 2024;30:2037-2048. ↗
  6. Katsi V, Koutsopoulos G, Fragoulis C, Dimitriadis K, Tsioufis K. Retatrutide-A Game Changer in Obesity Pharmacotherapy. Biomolecules. 2025;15:796. ↗
  7. Yin Y, et al. Efficacy of GLP-1 Receptor Agonist-Based Therapies on Cardiovascular Events and Cardiometabolic Parameters in Obese Individuals Without Diabetes: A Meta-Analysis of Randomized Controlled Trials. Journal of diabetes. 2025;17(4):e70082. ↗
  8. Melson E, et al. What is the pipeline for future medications for obesity? International journal of obesity (2005). 2025;49(3):433-451. ↗
  9. Caruso I, et al. Incretin-based therapies for the treatment of obesity-related diseases. npj metabolic health and disease. 2024;2(1):31. ↗
  10. Deravi M, et al. The "Weight" for a New Agent Is Almost Over: A Commentary on the Novel Triagonist Retatrutide for Obesity. The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians. 2024;40(6):300-305. ↗
  11. Kusminski CM, et al. Transforming obesity: The advancement of multi-receptor drugs. Cell. 2024;187(15):3829-3853. ↗
  12. Pillai AA, et al. Triple Hormone Receptor Agonism: The Role of Retatrutide in Addressing Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Comprehensive Review. Cardiology in review. 2026. ↗
  13. Pearson MJ, et al. Retatrutide And Lipid And Metabolite Profiles In Participants With Obesity With Or Without Type 2 Diabetes. The Journal of clinical endocrinology and metabolism. 2026. ↗
  14. Basile C, et al. Effect of incretin-based therapies on blood pressure: a systematic review and meta-analysis. European journal of preventive cardiology. 2026. ↗
  15. Wen Y, et al. Decreases in circulating ANGPTL3/8 concentrations following retatrutide treatment parallel reductions in serum lipids. Diabetes, obesity & metabolism. 2025. ↗